[PPT] - Company Presentation April 2017 1 Agenda 01 Sart rtorius in in PowerPoint Presentation

SLIDE 1

1

Company Presentation

April 2017

SLIDE 2

Agenda

Sart rtorius in in Brie rief

01 03 Lab

b Prod Products & Serv rvices Biopr ioprocess S Solu

lutio

ions

02 04 Sart

rtorius 2020 2020

05 Appe

ppendix ix

SLIDE 3

Sartorius in 2016

Figures as of Dec. 31, 2016; 1 Underlying EBITDA (excluding extraordinary items)

~€325 325 mn mn

Earnings1

~€1.3

.3bn bn

Sales revenue

Biopr

proce
cess a

and Labor borator

ry

Tech chnol

logie
gies P

Provide ider

Internationally leading EBITDA1 margin

Sales revenue by region

~€152 152 mn mn

Investments

~34% 4%

Americas

~44% 4%

EMEA

~22% 2%

Asia| Pacific

25. 25.0 %

Listed since 1990; Part of German TecDax

3

SLIDE 4

Global Player with around 50 Sales and Production Sites

Americas as

Production and Production/Sales

EM EMEA EA Asia ia|Pacif ific ic

Sales 4

SLIDE 5

More than 6,900 Employees Worldwide

Figures as of Dec. 31, 2016 5

~1,000 00

Americas

~4,850 50

EMEA

~1,050 50

Asia|Pacific

Dis iscov

ver Sartor
riu

ius

1995

1996

~7,000 00 3,000 00 4,000 00 5,000 00 2,000 00

1997 1998 1999 2001 2006 2002 2003 2004 2005 2008 2013 2009 2010 2011 2014

2000 2007 2012 2015 2016 2017

SLIDE 6

Our Corporate Values

6

SLIDE 7

Roots of Both Divisions Reach Far Back

Weighi ghing ng Techno hnolog

gy

Core of Lab Division

Filtratio ation

Mainstay of Bioprocess Division

University mechanician | Company founder Florenz Sartorius invents short-beam analytical balance Wilhelm Sartorius founds joint venture with Nobel laureate and creator of membrane filtration Richard Zsigmondy

1870 1870 1927 1927

7

SLIDE 8

8

1870 870 Florenz Sartorius founds precision machine workshop 2007 007 Biotechnology Division merges with Stedim to Sartorius Stedim Biotech 1927 927 Membrane filter company is founded 2011 011 New Division Lab Products & Services; Acquisition Biohit LH sinc nce 2012 012 Six Acquisitions in Bioprocess Solutions 1990 990 Initial public

ffering

Rebuilding after Second World War Mid id-90s 90s Positioning as biopharma supplier 2000 000 Acquisition

f B. Braun‘s fer-

mentation business Core company in Goettingen Expansion into Asia Around 50 sites worldwide International distribution Subsidiaries in Europe | North America 1870 870 1995 995 1980 980 1930 930 Today ay

Business Development Spanning More Than 140 Years

2016 016 Acquisitions of IntelliCyt and ViroCyt 2017 017 Acquisitions of Essen BioScience and Umetrics

SLIDE 9

Two Divisions

Share of Group sales based on figures as of Dec. 31, 2016 9

Premium lab instruments, consumables and services for R&D, QA and QC

Lab P Product cts & Service ces Biopro rocess ss Solu lutio ions

~75% 75%

f sales

~25% 25%

f sales

Innovative single-use prodcts and equipment for the manufacture of biologics

SLIDE 10

Agenda

Sartoriu

rius i

in Brie rief

01 03 Lab

b Prod Products & Serv rvices Biopr ioprocess S Solu

lutio

ions

02 04 Sart

rtorius 2020 2020

05 Appe

ppendix ix

SLIDE 11

What Are Biopharmaceuticals?

11

First-time or improved treatment of serious illnesses,

such as cancer, multiple sclerosis, rheumatism

Targets only diseased cells; fewer side effects
New vaccines

~20. 0.000 A 000 Atoms

R&D and production labor-intensive
High therapy costs: biologics ~ $50 vs.

chemical medications ~ $2 per day Living, genetically modified cells Production Injection | Infusion

Advan vantag tages Chal allenges

SLIDE 12

High initial cost Considerable cleaning effort Risk of cross-contamination

12

Trend towards Manufacturing Single-use Technologies

Pres esen ent Past st

+ CAPEX reduction over entire lifecycle + Lower water and energy consumption + Higher flexibility

SLIDE 13

BPS Generates Around 75% of its Business with Single-use Products

~ €975 975mn.

Single le-us use

~75%

Equipment nt

~25%

13 Figures as of Dec. 31, 2016

SLIDE 14

Total Solution Provider across the Biopharma Process Chain

14

Serv rvic ices Proce cess D ss Development nt Produ duction ion

Fermentation Purification Cell Harvesting Buffer | Preparation Cell Culture Media

SLIDE 15

Leading Market Positions Worldwide

>85 % of sales revenue generated from TOP 1-3 positions

Filtration TO TOP 3 Fluid Management #1

#1

Fermentation #1

#1

15

SLIDE 16

Agenda

Sartoriu

rius i

in Brie rief

01 03 Lab

b Prod Products & Serv rvices Biopr ioprocess S Solu

lutio

ions

02 04 Sart

rtorius 2020 2020

05 Appe

ppendix ix

SLIDE 17

Research Labs Need Intelligent Lab Instruments

17

Assistance systems reduce user errors
Laboratory data are processed

automatically

Ergonomic design minimizes physical

strain

SLIDE 18

Quality Assurance Labs Accompany every Step of Food and Pharma Production

18

Sample collection
Quality assurance
Clearance
Documentation

SLIDE 19

These Products and Services are Must-Haves in Any Laboratory

19

Balances
Pipettes
Lab Water Systems
Moisture Analyzers

Lab I Lab Instr truments Consumabl bles Se Services

Syringe Filters
Microbiological

Test Kits

Pipette Tips
Installation
Servicing | Repair
Qualification (IQ/OQ)
Calibration
Training

SLIDE 20

Lab Portfolio Recently Expanded into Bioanalytics

20

Innovative and unique bioanalytical platforms, combined from instruments, reagents

and software

Focus on customers from pharma/biotech and academia
Excellent fit between the two acquired companies and with existing LPS portfolio

Award-winning technology for cell screening Unique system for real-time live-cell imaging and analysis

Acquisition in June 2016 Acquisition in July 2016 Acquisition in April 2017

Innovative platform for rapid virus quantification

SLIDE 21

Expansion of Direct Sales including eBusiness

Distributors

ptimize

Direct sales expand eBusiness build up

Sal Sales Chann nnels ls

Pharma | Biotech Academia

Cl. Diagnostics|

Chemicals Food & Beverage

SLIDE 22

Leading Market Positions Worldwide

Average global market share >10%
Significant growth potential, especially in USA and Asia

Lab Balances #2

#2

Pipettes #4

#4

Lab Filtration #3

#3

Microb. Analysis #2

#2

(membrane based)

22

SLIDE 23

Agenda

Sartoriu

rius in

in Brie rief

01 03 Lab

b Prod Products & Serv rvices Biopr ioprocess S Solu

lutio

ions

02 04 Sart

rtorius 2020 2020

05 Appe

ppendix ix

SLIDE 24

Profitable Growth in Past 10 Years

1Underlying EBITDA (adjusted for extraordinary items); 2 Including Intec (Intec sales revenue = shaded area)

24

521.1 622.7 611.6 602.1 659.3 733.1 845.7 887.3 891.2

13.7 15.3 13.1 14.1 16.7 18.6 19.0 19.5 21.0 23.6 25.0

5 10 15 20 25 30 35 40

2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016

2

Sales revenue € in mn Underlying EBITDA1 margin in %

1,300.3 1,114.8

SLIDE 25

Ambitious Growth Targets Up to 2020

1 Based on 2015 exchange rates; 2 Excluding extraordinary items

25

Regi gional al

North America: Gain market share
Asia | esp. China: Leverage strong market growth

Strate tegic I Initiati atives 2020 2020 T Targe rgets

Portfolio

Expansion through alliances and acquisitions
Own product development

In Infrastructure

Expansion of production capacity
New global ERP system

~€2bn bn.

Sales Revenue

~26 26 - 27% 27%

EBITDA2 margin

~3/4 Organic ~1/4 Acquisitions

1 1

SLIDE 26

Gain Market Share in North America; Leverage Strong Market Growth in Asia

1 2011-2016, in constant currencies 2 Figures as of Dec. 31, 2016

26

Sales share2

Americas Asia |Pacific ~€1.3 bn. 34% 22%

Regional

~+18%

8%

CAGR1 Americas

~+14%

4%

CAGR1 Asia | Pacific North America: largest market for biopharma and lab products Asia: strongest-growing pharma and lab market

Mississauga Mexico City Yauco Bohemia Albuquerque

Production | Sales Sales

Singapore Kuala Lumpur Bangalore Hanoi Tokyo Beijing Seoul Hong Kong Bangkok Shanghai Suzhou

Production | Sales Sales

New Oxford Ann Arbor

SLIDE 27

Complementary Alliances & Acquisitions Add to Growth

27

Acqui uisitions ns | Allianc nces

27

Portfolio

2017 017 2000 000

As Aseptic ic Technolo logie ies Metro troglas LevTe Tech SAFC Bioscienc nces Raumedi edic Südpa pack Medic ica

B. Braun

aun Biote tech h Inter ernati nationa nal

Omnimark ark Corning ng c-LEc Ecta ta Umetri trics ABER ER ProMe Metic ic BlueS eSen ens TC TC Te Tech

Bio iohit it Liqui uid Hand ndling ng

Lonza C a Cell C ll Cult lture M Media ia

TAP P Biosy syst stems

BD BD AllPure re em em-tec BioOut utsour urce Cellc llca kSep ep ViroCy Cyt Intell lliC iCyt Ess Essen BioScience Toha ha Pla last st

Sted tedim Biosy syst stems

Wave B e Biotec ech Bayer Technology S Services NIR O Onlin line Bosch h Packagi ging Trace A Analy lytic ics

SLIDE 28

The Widest Product Portfolio Across the Biopharma Process Chain

Cell culture media Cell

Media a Prepar arati ation Seed d Fermentati tation Produ duction ion Fermentati tation Cel ell R Remo emoval | Clarif ific ication ion Viral al Clear aran ance

y y y y y y y y y y y y y y y y y y y

Antibodies Contaminents such as viruses Simplified diagram

y y y y

Media Preparation Seed Fermentation Production Fermentation Cell Removal Clarification Capture Polishing Virus Clearance

Downst nstream P m Proce cessi ssing ng Upstr tream am Proce cessi ssing

Vaccines, monoclonal antibodies, ...

Proce cess ss dev evel elopmen ent Portfolio

28

SLIDE 29

Support of process development Q3 2015 Testing in biosafety and bioanalytics Q2 2015 Small-scale single-use bioreactors Q4 2013 Cell culture media

Q1 2013

Single-use technology for sampling

Q2 2014

Bioprocess Portfolio Continuously Enhanced

Proce cess D ss Development nt Prod Production

n

Software for bioprocess data analysis

Q2 2017

Single-use centrifuges

Q3 2016

29

SLIDE 30

Alliances Speed up Innovation

30

Portfolio Development and supply partnership for novel polymer plastic films Ready-to-use, prefilled media products for microbiological applications Single-use sensors for biomass measurement

SLIDE 31

New Products

31

Single-use Clarification System

High flow rates, flexible scalability Portfolio

Innovative Operating Concepts

Fast and reliable results

Syringeless One-step Filters

Simple, multiplexing sample preparation

Modular Fermentation System

Parallel use of up to eight su bioreactors

SLIDE 32

Strong R&D in Core Technologies

32 32

Portfolio

Membranes, non-wovens
Plastics processing: Injection

molding, extrusion, welding|gluing

Sensors, automation & control
Bioanalytics & cell biology
Process analytics
Mechatronics

Technologies

Biotechnology and biopharma
Quality assurance and research

laboratories

Technology integration

Alliances Applications

SLIDE 33

1 2 Based on FY 2017 guidance

Incl. discontinued operation;

33 33

Infrastructure

Investments into Infrastructure Foster Profitable Growth

Significant expansion of production capacities initiated in 2016; earlier and to a greater

extent than initially planned due to continuing strong organic growth

Capacities at Yauco plant for single-use bags and filters will be more than doubled
Expansion of operations at headquarters in Goettingen, e.g. additional membrane

capacities

Further investments into digitalization (ERP, CRM, etc)

Capex ratio in %

8.8 .8 2016 2014 20131 20121 7.7 .7 2015 ~ 12 12-15 15 2017e2 11. 11.7 9.1 .1 10. 10.1

Expansion Production facility in Yauco | Puerto Rico

SLIDE 34

New Sartorius Campus to Further Boost Innovative Strength and Efficiency

34

Consolidation of the two major Goettingen sites into one site
New lab instruments building in operation
Further expansion of filter and membrane production capacity
Building to foster an advanced and open work environment and to provide more space

Infrastructure

SLIDE 35

Agenda

35

Sartoriu

rius i

in Brie rief

01 03 Lab

b Prod Products & Serv rvices Biopr ioprocess S Solu

lutio

ions

02 04 Sart

rtorius 2020 2020

05 Appe

ppendix ix

SLIDE 36

Expansion in Stages of Sartorius Campus

36

Lab Instruments Manufacturing Parking Lot R&D Membrane production College Facility Management Main Entrance | Administration

under constr. -

Receiving area Membrane casting machine Bioprocess Solutions Manufacturing Marketing | Cafeteria

under constr. -

Infrastructure

Existing buildings New Buildings

SLIDE 37

Next Steps

37

Main Entrance | Administration Marketing | Cafeteria

Under Construction

New main entrance and administration buildings:

completion and relocation in Q3 2017

Forum with application labs, offices, cafeteria; expected to be operational by end of 2018

Infrastructure

SLIDE 38

38

Portfolio Bioprocess Solutions

Filtration Purification

SLIDE 39

39

Fluid Management Fermentation & Cell Culture Media

Portfolio Bioprocess Solutions

SLIDE 40

40

Portfolio Lab Products & Services

Lab Balances Pipettes

SLIDE 41

41

Lab Water Systems Further Lab Instruments

Portfolio Lab Products & Services

Bioanalytical Technologies

SLIDE 42

42

Lab Filtration Microbiological Quality Control

Portfolio Lab Products & Services

SLIDE 43

Questions & Answers

43

SLIDE 44

Disclaimer

This presentation contains statements concerning Sartorius Groups’ future performance. These statements are based on assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we cannot guarantee that they will actually materialize. This is because our assumptions harbor risks and uncertainties that could lead to actual results diverging substantially from the expected ones. It is not planned to update our forward-looking statements. Throughout this presentation, differences may be apparent as a result of rounding during addition.

44